V1
[research]surgical · service · 0 deployments in catalog
Verified: Vicarious Surgical (Waltham MA area; went public via SPAC 2021, NYSE: RBOT) is developing the V1 single-port robot. The differentiators (9-DoF human-like instrument, immersive interface) are engineering concepts in animal-lab / design-freeze stage., Current status: DISTRESSED (the headline): Q1 2026 10-Q carries an EXPLICIT going-concern substantial-doubt. Cash + short-term investments = $3.682M (3/31/2026); runway only through Q2 2026. Q1 2026 net loss $7.329M; ZERO revenue ever (never commercialized). NYSE trading suspended Mar 3 2026, delisting commenced; moved to OTCQB Mar 24 2026. A reverse split was used as a survival maneuver., Maturity = research (gating not even submitted): NO FDA clearance and NO FDA submission yet (planned De Novo, first-in-human repeatedly delayed). V1 does nothing commercial: no revenue, no installed base, no cleared device. NO clearance = research-tier. At material risk of becoming discontinued within the runway window. RE-VERIFY within weeks given the Q2-2026 cash cliff., Claimed but NOT verified: Any completed first-in-human procedure; a firm/met FDA submission date; that the company remains a going concern past Q2 2026; successful Nasdaq relisting; AI-assist or autonomy (none cleared or commercial; teleoperated by design)., Re-verify 2026-06-03: Distress intact (Q1 2026 10-Q, filed Apr 30 2026: cash + ST investments $3.682M at 3/31/2026, runway through Q2 2026, Q1 net loss $7.329M, accumulated deficit $253.446M, still zero revenue, still NO FDA submission / NO first-in-human). NEW defensive action: applied to UPLIST to the Nasdaq Capital Market + filed a preliminary proxy for a board-authorized reverse stock split (ratio TBD) - both INTENTIONS/applications, NOT completed (does not yet meet Nasdaq initial-listing requirements). No bankruptcy, acquisition, or new financing closed. No lifecycle change; maturity stays research.
Manufacturer
Vicarious SurgicalForm Factor
surgical
Lifecycle
research
Operational Reality
Teleoperated
Deployments
0
Target Price
Custom Quote
- SURGICAL
- RESEARCH
Description
Vicarious Surgical (based in the Waltham, Massachusetts area; public via a 2021 SPAC merger as NYSE: RBOT) is developing the V1, a single-port surgical robot concept built around a 9-degree-of-freedom human-like instrument and an immersive virtual-reality-style surgeon interface meant to transport the surgeon inside the patient. The headline finding is the company's distress: its first-quarter 2026 Form 10-Q carries an explicit going-concern substantial-doubt, with cash and short-term investments of $3.682 million as of March 31, 2026 and a stated runway only through the second quarter of 2026, a quarterly net loss of $7.329 million, and zero revenue ever, since the product has never been commercialized; NYSE trading was suspended on March 3, 2026 with delisting proceedings commenced, and the stock moved to the OTCQB on March 24, 2026 after a reverse split used as a survival maneuver. The registry records V1 at research maturity, because it has no FDA clearance and not even an FDA submission yet, with its planned De Novo pathway and first-in-human study repeatedly delayed, so under the verified-vs-claimed framework no clearance means research-tier regardless of years of demonstrations, and the differentiators remain engineering concepts in animal-lab and design-freeze stage. The lifecycle is recorded as active but materially at risk of becoming discontinued within the cash-runway window, and this record should be re-verified within weeks given the Q2-2026 cliff.
Key facts & specs
- website
- https://www.businesswire.com/news/home/20260303-vicarious-surgical-nyse-delisting
- lifecycle
- active
- manufacturer
- Vicarious Surgical
- Maturity stage
- research
- Dof
- 9
- Console
- immersive virtual-reality-style surgeon interface
- Products
- V1: single-port system with a '9-DoF human-like' instrument and an immersive VR-style surgeon interface ('transport the surgeon inside the patient'). Pre-commercial; no FDA submission yet.
- Form Factor
- surgical (single-port surgical robot concept: 9-DoF human-like instrument + immersive VR-style surgeon interface)
- Fda clearance
- none
- Visualization
- virtual-reality-style
- Autonomy level
- teleoperated by design
- Maturity
- research
- Cash and short-term investments
- $3.682 million as of March 31, 2026
- Runway
- through Q2 2026
- Q1 2026 net loss
- $7.329 million
- Accumulated deficit
- $253.446 million
- Revenue
- zero (never commercialized)
- F D A submission
- none yet
Autonomy: verified vs claimed
Teleoperated (human-controlled)
Independent audit: evaluates human teleoperation reliance, VR assistance, and vendor autonomy bounds.
Autonomous robotics system.
Safety record
No incidents on record for V1.
FAQ
What is V1?
Vicarious Surgical (based in the Waltham, Massachusetts area; public via a 2021 SPAC merger as NYSE: RBOT) is developing the V1, a single-port surgical robot concept built around a 9-degree-of-freedom human-like instrument and an immersive virtual-reality-style surgeon interface meant to transport the surgeon inside the patient. The headline finding is the company's distress: its first-quarter 2026 Form 10-Q carries an explicit going-concern substantial-doubt, with cash and short-term investments of $3.682 million as of March 31, 2026 and a stated runway only through the second quarter of 2026, a quarterly net loss of $7.329 million, and zero revenue ever, since the product has never been commercialized; NYSE trading was suspended on March 3, 2026 with delisting proceedings commenced, and the stock moved to the OTCQB on March 24, 2026 after a reverse split used as a survival maneuver. The registry records V1 at research maturity, because it has no FDA clearance and not even an FDA submission yet, with its planned De Novo pathway and first-in-human study repeatedly delayed, so under the verified-vs-claimed framework no clearance means research-tier regardless of years of demonstrations, and the differentiators remain engineering concepts in animal-lab and design-freeze stage. The lifecycle is recorded as active but materially at risk of becoming discontinued within the cash-runway window, and this record should be re-verified within weeks given the Q2-2026 cliff.
Is V1 actually deployed in the real world?
V1 is at the research stage: it exists, but DEPLOY has no verified real-world deployment on record. Manufacturer capability claims should be read as claims pending independent verification.
Who makes V1?
V1 is made by Vicarious Surgical, based in Waltham, Massachusetts, USA, founded in 2014.
Can you buy V1?
V1 is at research stage and is not yet available for sale.
What are alternatives to V1?
On the DEPLOY registry, comparable surgical robots to V1 include da Vinci (and Ion), Edge Multi-Port Surgical Robot, Edison Histotripsy System, Stryker Mako SmartRobotics.
How does V1 compare to da Vinci (and Ion)?
V1 and da Vinci (and Ion) (Intuitive Surgical · 15 deployments) are both surgical robots on the DEPLOY registry. V1 has 0 verified deployments on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.
Is V1 a top surgical?
On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, V1 ranks in roughly the top 12% of surgical models tracked by the registry.
What is V1's maturity stage?
V1 is at the research stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Research stage means active development without commercial deployments on file.
Where is V1 deployed?
No verified deployments of V1 are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.
Is V1 safe?
V1 has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.